Recently Viewed
Clear All$0.99
$0.00
(-0.39%)
As on 02-Apr-2026 15:39EDT
Today’s Range
52 Week Range
Liquidity
Market cap
$31 Mln
Revenue (TTM)
$1 Mln
Net Profit (TTM)
$0 Mln
ROE
-1.3 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
2.3
Industry P/E
--
EV/EBITDA
-3.6
Div. Yield
0 %
Debt to Equity
0
Book Value
$--
EPS
$-1.1
Face value
--
Shares outstanding
31,195,891
CFO
$-198.44 Mln
EBITDA
$-277.50 Mln
Net Profit
$-269.39 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Actinium Pharmaceuticals Inc. (Delaware) (ATNM)
| -27.5 | -16.4 | -27.5 | -33.8 | -52.9 | -34.3 | -33.7 |
|
BSE Sensex
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Actinium Pharmaceuticals Inc. (Delaware) (ATNM)
| 7.9 | -74.9 | -52.3 | 77.2 | -22.9 | 19.4 | -43.7 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Actinium Pharmaceuticals Inc. (Delaware) (ATNM)
|
1.0 | 30.9 | 0.9 | -34.6 | -3,844.3 | -175.3 | -- | 2.3 |
| 61.0 | 8,072.9 | 1,091.0 | 202.3 | 31.6 | 31.3 | 36 | 14.2 | |
| 229.3 | 13,405.2 | 691.7 | -219.0 | -13.7 | 163.2 | -- | 14.6 | |
| 66.7 | 7,755.6 | 88.0 | -785.0 | -808.1 | 197.5 | -- | 60.3 | |
| 43.9 | 11,247.3 | 2,320.1 | 782.6 | 39.0 | 35.5 | 14.9 | 5.0 | |
| 93.8 | 11,306.9 | 982.0 | -416.3 | -42.1 | 348.4 | -- | 55.7 | |
| 7.3 | 6,847.2 | 113.3 | -351.4 | -211.0 | 71.1 | -- | 0.0 | |
| 546.9 | 11,592.5 | 958.4 | -288.3 | -27.8 | -42.5 | -- | 16.8 | |
| 498.3 | 13,063.9 | 2,530.2 | 451.1 | 21.3 | 70.2 | 30.1 | 28.0 | |
| 310.4 | 7,699.1 | 0.0 | -303.3 | -- | -45.8 | -- | 8.8 |
Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. The company advances two clinical stage product candidates,... Actimab-A, to treat patients with myeloid malignancies including acute myeloid leukemia and myelodysplastic syndromes; and Iomab-ACT, to improve patient access to and outcomes with cellular therapies, such as CAR-T for various blood cancer indications and gene therapies for non-malignant hematologic disorders such as sickle cell disease. It also develops ATNM-400, a preclinical non-prostate specific-membrane antigen targeting radiotherapy utilizing the Actinium-225 radioisotope for patients with prostate cancer. In addition, the company's Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). Further, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies, and its research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company is based in New York, New York. Address: 100 Park Avenue, New York, NY, United States, 10017 Read more
Chairman & CEO
Mr. Sandesh C. Seth M.B.A., M.S.
Chairman & CEO
Mr. Sandesh C. Seth M.B.A., M.S.
Headquarters
New York, NY
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Actinium Pharmaceuticals Inc (Delaware) (ATNM) is $0.99 (NYSE) as of 02-Apr-2026 15:39 EDT. Actinium Pharmaceuticals Inc (Delaware) (ATNM) has given a return of -52.92% in the last 3 years.
Since, TTM earnings of Actinium Pharmaceuticals Inc (Delaware) (ATNM) is negative, P/E ratio is not available.
The P/B ratio of Actinium Pharmaceuticals Inc (Delaware) (ATNM) is 2.33 times as on 31-Mar-2026, a 41 discount to its peers’ median range of 3.94 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2024
|
-1.03
|
1.20
|
|
2023
|
-2.88
|
3.86
|
|
2022
|
-8.28
|
4.11
|
|
2021
|
-5.23
|
1.76
|
|
2020
|
-6.45
|
2.34
|
The 52-week high and low of Actinium Pharmaceuticals Inc (Delaware) (ATNM) are Rs 1.95 and Rs 0.95 as of 03-Apr-2026.
Actinium Pharmaceuticals Inc (Delaware) (ATNM) has a market capitalisation of $ 31 Mln as on 31-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Actinium Pharmaceuticals Inc (Delaware) (ATNM), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.